YIH
CBIO

Y-Intercept (HK)’s Crescent Biopharma CBIO Stock Holding History

Y-Intercept (HK)’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$915K Buy
+50,824
New +$992K 0.02% 1086
2024
Q2 		– Sell
-431
Closed -$129K – 1572
2024
Q1 		$129K Buy
431
+165
+62% +$49.3K 0.01% 1243
2023
Q4 		$62.7K Buy
+266
New +$41.4K 0.01% 1142

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Y-Intercept (HK)'s CBIO Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 50,824 shares worth $915K. The stake represents 0.02% of the portfolio and ranks #1086 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CBIO as recently as Q1 2024.

Y-Intercept (HK) first reported a position in CBIO in Q4 2023 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Y-Intercept (HK) held 50,824 shares of Crescent Biopharma worth $915K as of Q2 2026.
  • Crescent Biopharma was a new Y-Intercept (HK) position in Q2 2026.
  • Crescent Biopharma made up 0.02% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1086 holding.
  • Y-Intercept (HK) first reported a position in Crescent Biopharma in Q4 2023 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.